US equities |
NVDA $241.38 ▲+1.04% SPCX $173.46 ▲+1.39% MU $1,050.81 ▼-1.24% AMD $630.33 ▼-0.22% MRVL $287.55 ▲+6.01% META $744.26 ▲+0.32% TSLA $382.11 ▲+0.89% SNDK $1,674.99 ▼-1.71%
FinancialContent

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

23.75 -0.26 (-1.08%)
Delayed Quote Updated: 9:36 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces $120 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
From Alto Neuroscience, Inc.
Via Business Wire
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗
Alto Neuroscience reports a narrower-than-expected Q3 2025 loss and advances its precision psychiatry pipeline, with cash extending into 2028. 
Via Chartmill
News headline image
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
These stocks are moving in today's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >